Kornimate/medical-research-clean huggingface dataset:
cxcl9 and cxcl11 levels in patients with autoimmune thyroiditis and habitual abortions

Conditions: Habitual Abortion

Summary: the purpose of this study is to measure serum cxcl9 and cxcl11 levels in patients with autoimmune thyroiditis and habitual abortions


Eligibility criteria:
inclusion criteria: * non-pregnant women with euthyroid autoimmune thyroiditis and a history of first trimester recurrent spontaneous abortions exclusion criteria: * 1) presence of acute or chronic systemic diseases; 2) other autoimmune diseases; 3) pregnancy and lactation over the previous 6 months; 4) evidence of infectious diseases in the last 3 months; 5) treatment with drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs, amiodarone, and lithium; 6) clinical history of hyperthyroidism and/or the presence of anti-tsh receptor antibodies.
bedtime administration of amlodipine versus lisinopril

Conditions: Hypertension

Summary: this study seeks to compare the differences in effectiveness among individual patients treated at for hypertension with bedtime administration of amlodipine versus lisinopril. there will be an analysis of whether one medication was more effective than another and whether specific patient factors could predict who responded better to which one.


Eligibility criteria:
inclusion criteria: * age 40 to 80 * newly diagnosed hypertension based on 24 hour ambulatory blood pressure monitor criteria. * minimum asleep sbp mean of ≥ 120mmhg for inclusion. exclusion criteria: * current antihypertensive medication use * baseline gfr \< 45 * preexisting macroproteinuria * chronic congestive heart failure * history of cva * diabetes mellitus * pregnancy * night-shift work * other preexisting contraindication to amlodipine or lisinopril

Keywords: managed with bedtime administration of lisinopril versus amlodipine
the influences of single chamber vs. multi-chamber blood flow restriction cuffs with bicep curls

Conditions: Blood Vessel Disease; Muscle Edema

Summary: the purpose of this study is to investigate the use of single (sc) and multi-chamber (mc) blood flow restriction (bfr) cuff bicep exercise on indices of arterial stiffness, muscle morphology, and participant perception.

twenty six adults aged 18-40 years old will undergo three treatment sessions (control (no bfr), sc bfr, and mc bfr) in a randomized order separated by one week. a familiarization session will also occur one week before starting the treatment period. each subject will undergo a series of tests including anthropometry, ultrasonography of the carotid artery, applanation tonometry, ultrasonography of the vastus lateralis, blood pressure acquisition, body composition, and maximal strength assessments (1rm). the exercise trial will consist of sets of dumbbell bicep curls performed to failure with a 2-seconds concentric and 2-seconds eccentric cadence, at 20% of their 1rm using 60% of the supine limb occlusion pressure (lop) with 1-minute rest intervals. assessments will be performed immediately before and after the exercise bout during each treatment session. two-way anovas will be used to examine the main effects of treatment and treatment-order interaction on pulse wave velocity, muscle cross-sectional area, and perceptual response.

Eligibility criteria:
inclusion criteria: 1. physically active (\> 1,000 met/min/wk) for at least six months. 2. weight stable for previous 6 months (+/-2.5 kg) 3. female subjects only- reported regular menstrual cycles for the last 2 years exclusion criteria: 1. bp\>140/90 mmhg 2. bmi\>40 kg/m2 3. diabetes 4. familial hypercholesterolemia 5. past or current history of chd, stroke or major cvd events. respiratory diseases (not including asthma), endocrine or metabolic, neurological, or hematological disorders that would compromise the study or the health of the subject. 6. women must not be pregnant, plan to become pregnant during the study, or be nursing 7. active renal or liver disease 8. all medications and supplements that influence dependent variables\* 9. recent surgery \< 2 months 10. alcohol abuse 11. sleep apnea 12. claustrophobia
the effect of lumbopelvic non-thrust spinal manipulation on individuals with low back pain

Conditions: Low Back Pain

Summary: the purpose of this experiment is to determine the effects of a non-thrust manipulation procedure on muscle function, spinal mobility, and pain level on those experiencing low back pain (lbp) in a sample of individuals who identify english as their primary language. the rationale for this language criterion is provided in section 9:f of this application. muscle function will be measured via the muscle thickness of a deep spinal stabilizing muscle (multifidus, mf) while in both a resting state and during a maximum voluntary contraction (mvc). spinal mobility will be measured as the active range of motion of both forward and backward trunk bending. pain level will be a self-report measure recorded during rest and active range of motion. hypothesis 1: a non-thrust manipulation procedure will increase the thickness of the sacral multifidus both at rest and during a maximum voluntary contraction hypothesis 2: a non-thrust manipulation procedure will result in greater low back active range of motion. hypothesis 3: a non-thrust manipulation procedure will result in a reduction in the participant's self-reported pain levels both at rest and during active range of motion movements.

the proposed study aims to determine if the impact of a newly-described manual procedure, that includes a non-thrust force applied to the low back region, has an impact on patient centered-outcomes. rehabilitation ultrasound imaging (rusi) will be used to determine mf muscle thickness (mt) at rest and during a maximum voluntary contraction (mvc) immediately following application of the manual procedure.

Eligibility criteria:
inclusion criteria: 1. participants are individuals with current complaint of low back pain, defined as pain that is present in the region from just below the rib cage to just below the buttocks. 2. participants will be 18 years of age or older 3. participants must be experiencing an episode of low back pain at the present time that is at any level on a numerical pain rating scale \& pain diagram (nprs) from 1-10 4. participants must demonstrate the ability to maintain standing and prone postures for several minutes at a time and perform lumbar active range of motion in a standing position 5. participants must report the presence of their low back pain during performance of active forward and/or backward bending in standing 6. participants must demonstrate the ability to communicate in conversational english, that includes speaking, reading, and writing. exclusion criteria: 1. participants who are currently involved in litigation that is directly related to the participant's current episode of low back pain 2. participants with known or suspected pregnancy 3. participants with confirmed diagnosis of any of the following conditions: * central nervous system disorder * rheumatoid arthritis * spinal fracture * spondyloarthropathy (i.e., ankylosing spondylitis) * tumor or infection of the spine
validation of plantar orthoses for abnormal plantar arch using a new non-invasive clinical imaging system

Conditions: Flat Feet; High Arched Foot

Summary: the goal of this project is to validate a new non-invasive clinical imaging system to evaluate the efficacy of plantar orthotics and to assess the biomechanical efficiency of plantar orthotics for people with flat or high arch feet. the cryovizion system should detect changes in participants' posture with an accuracy of 95%, while orthotics should improve the body's postural symmetry index.


Eligibility criteria:
inclusion criteria: * bmi\<30 * no pain * no musculoskeletal disorders * no balance disorders * no pathologies linked to the central nervous system * no use of drugs affecting the balance exclusion criteria: * people with foot pathology other than the arch; * people with diabetes ; * people with severe obesity ; * people wearing high heel shoes regularly ; * people with degenerative disease ; * people with neuromuscular pathology ; * people with a circulatory disorder ; * people who have had major lower body surgery; * inability to walk 30 minutes continuously.
a study to assess the efficacy and safety of hh-120 nasal spray for the treatment of mild covid-19

Conditions: COVID-19

Summary: this is a randomized, double-blind, placebo-controlled phase 2 study in participants over the age of 18 years with mild covid-19. the main purpose of this study is to evaluate the effect on viral load clearance and clinical recovery, and safety of hh-120 nasal spray in participants over the age of 18 years with mild covid-19 (according to the fda definition, 2021).


Eligibility criteria:
inclusion criteria: * participants who are ≥18 years of age . * participants who are diagnosed with mild covid-19 and with laboratory confirmed of sars-cov-2 infection as determined by pcr or antigen test. * participants who agree to use highly effective methods of contraception. women of childbearing potential (wocbp) must have a negative urine pregnancy test result. * participants who are willing and able to provide written informed consent, or with a legal representative who can provide informed consent. exclusion criteria: * have suspected or proven serious disease (cardiovascular, renal, liver systems, etc.), active bacterial, fungal, viral, or other infection (except covid 19) that in the opinion of the investigator could constitute a risk when taking the study intervention. * bronchial asthma or chronic obstructive pulmonary disease （copd). * urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or extracorporeal membrane oxygenation(ecmo). * have prior use (unless required as rescue medication) of any of the following treatments: covid 19 investigational or emergency use authorization (eua) approved treatment, including but not limited to convalescent plasma, mabs against sars cov 2, intravenous immune globulin (ivig) (any indication), where prior use is defined as the past 30 days or less than 5 half lives of the investigational product (whichever is longer) from screening. * history of anaphylaxis or other significant allergy in the opinion of the pi or known allergy or hypersensitivity to any of the components of the study intervention.
intravitreal triamcinolone for clinically significant diabetic macular oedema that persists after laser treatment (tdmo)

Conditions: Diabetic Macular Oedema

Summary: the trial will test the hypothesis that an intravitreal injection of triamcinolone is safe and efficacious for patients with clinically significant diabetic macular oedema that is recalcitrant to conventional laser therapy

diabetic retinopathy is a common cause of severe loss of visual and the most common cause of legal blindness in individuals between the ages of 20 and 65 years in developed countries. swelling of the central retina, or "macular oedema" is the commonest cause of visual loss in diabetic retinopathy. diabetic macular oedema is treated with laser coagulation to the macular area according to established guidelines which take into account the extent of the leak and its proximity to the centre of the macula, the "fovea". this treatment does not, however, always work and is inherently destructive. intravitreal injection of crystalline steroids has been proposed as a new modality to treat clinically significant diabetic macular oedema. to determine by means of a prospective, double-masked, randomised, placebo-controlled trial to determine whether an intravitreal injection of triamcinolone three months or more after focal or grid laser photocoagulation for clinically significant diabetic macular oedema will improve the visual acuity of eligible eyes. oct will be used in addition to visual acuity testing as an objective measurement of macular oedema.

Eligibility criteria:
inclusion criteria: * clinically significant diabetic macular oedema involving the fovea in one or both eyes (phakic and/or pseudophakic) which persists at least 3 months after adequate macular photocoagulation. * best corrected visual acuity in the affected eye(s) 6/9 or worse exclusion criteria: * glaucoma which is uncontrolled or is controlled but with glaucomatous visual field defects * loss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration) * significant macular ischemia (ffa) * no useful vision in fellow eye * known allergies to triamcinolone acetate or steroids * patient is already under systemic treatment with \> 5mg prednisolone (or equivalent) daily. * intercurrent severe disease such as septicaemia * any condition which would affect follow-up or photographic documentation (e.g. geographical, psycho-social, media opacities)

Keywords: diabetic macular oedema triamcinolone acetate intravitreal injection clinical trial laser treatment
telemonitoring platform "cureety techcare" vs standard of care for mtbnc patients initiating a first-line treatment

Conditions: Metastatic Triple-Negative Breast Carcinoma

Summary: the goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "cureety techcare"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy. the main questions it aims to answer are: * is patient quality of life improved by using the telemonitoring platform? * are patients hospitalized less frequently when using the telemonitoring platform? * is the patient overall survival improved by telemonitoring ? researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care. participants using telemonitoring will answer questions about their symptoms on the platform. the platform will analyze these symptoms, assess the patient's general condition and provide advice accordingly. medical staff will also access the platform to monitor the patient's general condition and contact them if necessary.


Eligibility criteria:
inclusion criteria: * signed a written informed consent form prior to participate in the study. note: in case of physical incapacitation, a trusted representative of their choice, which is not the investigator or sponsor, can sign on the behalf of the patients * patients ≥18 years of age. * patient with histologically documented metastatic triple negative breast cancer (er (oestrogen receptor) and pr (progesterone receptor) \<10%, her2 negative status). * life expectancy \> 6 months as per investigator estimate. * patient initiating a marketed authorized first-line systemic treatment in the metastatic setting. * eastern cooperative oncology group (ecog) performance status (ps) ≤2. * patient having completed the eortc qlq-c30 and eortc qlq-br45 at baseline (response to questions 29 and 30 of eortc qlq-c30 at baseline are mandatory) * affiliated to the social security system or equivalent health insurance. * patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines) * patient has access to a computer, tablet, or smartphone connected to the internet. exclusion criteria: * participation in another clinical trial using telemonitoring. * physical or psychological incapacity of the patient to use the digital telemonitoring cureety techcare, according to the investigator's discretion. * patient deprived of their liberty or under protective custody or guardianship.

Keywords: telemonitoring triple negative breast cancer cureety adverse events
phrenic nerve reconstruction for the treatment of diaphragmatic paralysis: patient experiences and reported outcomes.

Conditions: Diaphragmatic Paralysis; Pain, Chest; Breath Shortness

Summary: this study utilizes a grounded theory methodology to explore patient experiences of phrenic nerve reconstructive surgery as a treatment for diaphragmatic paralysis.


Eligibility criteria:
inclusion criteria: * individuals with a confirmed diagnosis of diaphragmatic paralysis. * individuals who are scheduled to undergo phrenic nerve reconstructive surgery for the treatment of diaphragmatic paralysis. exclusion criteria: - individuals who do not comprehend the english language.

Keywords: grounded theory diaphragmatic paralysis diaphragm respiratory system pain
clinical trial examining effects of monosodium glutamate (msg) on irritable bowel syndrome (ibs) and fibromyalgia (fm)

Conditions: Irritable Bowel Syndrome; Fibromyalgia

Summary: objective: randomized, double blind, placebo-controlled, crossover, clinical trial to examine the effects of the food additive glutamate (in the form of msg) on ibs and fibromyalgia. setting and subjects: the fibromyalgia research database at ohsu will be utilized to identify and recruit fibromyalgia patients who also have ibs to ohsu study centers. intervention: approximately 60 male and female subjects aged 18-75 will be placed on a 1-month glutamate-free elimination diet. those that respond positively to the diet (we are estimating 30-40 subjects), will then be randomized to receive either a citrus drink containing 5 grams of msg; or placebo (the citrus drink alone)on three consecutive days one week apart. the investigators are hypothesizing that those who react positively to the elimination diet will have symptom occurrence statistically more frequently when given the glutamate challenge, than when given placebo.


Eligibility criteria:
inclusion criteria: * men and women aged 18-75 who fulfill criteria for irritable bowel syndrome (ibs) and fibromyalgia (fm) * they must live in the greater portland, or, metro area, have transportation to/from study site, have access to email * willing to discontinue medications with bowel altering side effects exclusion criteria: * asthma * inflammatory bowel disease * colon cancer or active endometriosis * any major abdominal surgery (excluding caesarean section, tubal ligation, hernia repair, gall bladder removal or appendectomy) * female and pregnant * currently taking pregabalin, gabapentin, or anti-psychotic medications and are unwilling/ unable to discontinue use * suffered from alcohol/substance abuse or psychosis in the last two years.

Keywords: irritable bowel syndrome fibromyalgia glutamate diet food additives
topography versus non-topography-guided prk with cxl in keratoconus

Conditions: Keratoconus

Summary: to our knowledge, this study is one of the first to compare the visual results of non-topography-guided and topography-guided photorefractive keratectomy (prk) applying sequential and simultaneous corneal cross-linking (cxl) treatment for keratoconus. considering recent advances in cross-linking and imaging in keratoconus, the outcomes of this study can lead us to several non-invasive algorithm management options.

interventional and comparative prospective study: sixty-nine eyes (38 patients) suffering from keratoconus (stages 1-2 amsler-krumeich classification) were divided into four groups. the four groups underwent topography- and non-topography-guided prk with sequential and simultaneous cxl. the main outcome measures were pre- and postoperative uncorrected distance visual acuity (udva), best corrected distance visual acuity (cdva), manifest refraction, contrast sensitivity, and keratometry.

Eligibility criteria:
inclusion criteria * age 34 (range from 34 to 41) * stable corneal topography and refraction for at least six months * estimated residual bed thickness of \>410 µm exclusion * presence of macular or retinal disease, * dry eye * history of recurrent corneal erosions * anterior segment abnormalities * unstable refractive error * post-surgically residual stromal bed thickness of under 350 mm * autoimmune disease * collagen vascular disease * immunosuppressive therapy or current use of systemic corticosteroids * diabetes mellitus * pregnancy * lactation
african american knowledge optimized for mindfully healthy adolescents

Conditions: Depression

Summary: the purpose of this study was to better understand how african american families identify and treat emotional and behavioral concerns associated with depression in their adolescent youth. the goals of the study included (a) identifying factors associated with participation in psychiatric research and treatment and (b) developing an intervention to increase participation in psychiatric research and treatment.

the aim of this study was to obtain an in-depth understanding of african americans' perceptions of barriers to adolescent and family engagement in psychiatric treatment and research utilizing a mixed methods approach in two phases. phase i consisted of data collected via surveys, focus groups and individual interviews with african american adults and youth. the data generated in phase i provided a foundation for the domains incorporated into manual development and therapist training procedures of the subsequent intervention phase of the project (phase ii). after the research team developed the depression treatment engagement intervention, the intervention was pilot tested in a sample of depressed african american youth and families (phase ii)

Eligibility criteria:
inclusion criteria: * persons who self-identify as black or african american * adolescents aged 11 to 17 at the time of recruitment * adult parents * parent consent and adolescent assent * demonstrated cognitive ability to understand participation exclusion criteria: * diminished capacity to participate
thoracic spine manipulation for patients with thoracic spine pain

Conditions: Pain

Summary: the study includes two phases. in phase one the reliability of thoracic spine mobility measurements are studied in subjects with thoracic spine pain. in phase two the reliable measurements are used to measure the effects of thoracic spine manipulation in subjects with thoracic spine pain. the changes in pain is measured as well. in second phase the control group receives tns treatment six times at home as a placebo so that the power of tns is limited to very low level. the number of treatments are controlled as well as the time of treatment. the treatment group receives six manipulation treatments within 3 week period. the effects are measured immediately after the treatment weeks, and 3 and 8 week follow-up. moreover the one year follow-up will be performed by mail questionnaire.

outcome measures are intensity of pain (vas, roland-morris questionnaire) thoracic mobility (measured with computer, tape measurements, inclinometer and manually).

Eligibility criteria:
inclusion criteria: * thoracic spine pain, * 18-55 years old exclusion criteria: * inflammatory spine disease, * previous surgery on thoracic spine area, * osteoporosis

Keywords: thoracic spine, pain, manipulation